Postoperative Yanghe decoction regimen improves outcomes for idiopathic granulomatous mastitis

A retrospective cohort study

Xing Zhang, MD\textsuperscript{a,}\textsuperscript{∗}, Jing Li, MD\textsuperscript{b}, Xian-Jie Hu, MD\textsuperscript{a}

Abstract

The etiology of idiopathic granulomatous mastitis (IGM), a rare inflammatory breast disease, is not understood. There is no consensus regarding the treatment of IGM. The purpose of this study was to determine the efficacy of surgery combined with traditional Chinese medicine for the treatment of IGM.

We retrospectively analyzed 53 patients of IGM who were treated with surgical excision at our hospital. Group A (n = 25) included patients treated with only surgery, and Group B included patients treated with surgery combined with postoperative Yanghe decoction. The clinical data were compared between the 2 groups, including demographics, clinical characteristics, and outcomes.

All patients were female with a mean age of 34.6 ± 5.9 years. There were no significant differences between the groups regarding preoperative demographics or clinical characteristics. The follow-up time was comparable between the groups (13.2 ± 10.0 vs 12.0 ± 10.2 months). Patients in Group B had shorter complete remission (CR) times than patients in Group A (76.1 ± 15.2 vs 84.0 ± 12.2 days; \textit{P} < .05). The CR rate was higher in Group B than in Group A (96.4% vs 76.0%; \textit{P} < .05), and the recurrence rate was lower in Group B than in Group A (0% vs 16.0%; \textit{P} < .05).

The postoperative Yanghe decoction regimen was associated with more rapid recovery after IGM surgery. Surgical management combined with postoperative oral Yanghe decoction treatment yielded a higher CR rate and lower recurrence rate than surgery alone. The effect of traditional Chinese medicine in IGM treatment requires further study.

Abbreviations: CR = complete remission, IGM = granulomatous mastitis, TCM = Traditional Chinese medicine.

Keywords: granulomatous mastitis, surgery, traditional Chinese medicine

1. Introduction

Idiopathic granulomatous mastitis (IGM) is a rare, chronic benign inflammatory breast disease that affects women of childbearing age and was first described by Kessler and Woloch in 1972.\textsuperscript{(1)} The etiology of the disease remains poorly understood. Factors including breast trauma, infection, and autoimmune processes may play a role.\textsuperscript{(2)} At present, there is a lack of consensus and guidelines regarding surgical and medical approaches to treat IGM.\textsuperscript{(3)} The primary treatments include corticosteroids, surgical intervention, and methotrexate.\textsuperscript{(4–7)} Treatment with oral corticosteroids generally requires at least 2 to 3 months and can result in substantial side effects. Methotrexate is also a drug with many adverse reactions, especially when used for long periods, and is not generally used to treat IGM. Failure to respond to steroids frequently leads to surgical excision. Surgery can achieve rapid regression of IGM; however, recurrence even after a bilateral mastectomy is not rare.\textsuperscript{(2,7)} Therefore, the most effective therapy with the least adverse drug reactions is worth investigating.

The role of traditional Chinese medicine (TCM) in the treatment of IGM has not been studied previously. To the best of our knowledge, this is the first study to focus on a new method using surgery combined with oral postoperative TCM in the treatment of IGM.

2. Materials and methods

2.1. Case selection

The study was conducted retrospectively in the Department of Thyroid and Breast Surgery, The Affiliated People’s Hospital of Ningbo University. We analyzed the clinical data and information of 53 patients diagnosed with IGM between January 2015 and
May 2019. All patients were female with a mean age of 34.6 ± 5.9 years. Patients were divided into 2 groups: Group A (n = 25) included patients treated with only surgery and Group B included patients treated with surgery combined with postoperative Yanghe decoction. The data and information were collected from our institutional medical record electronic information system, including all data from patients who received treatment during this period. Patients were included when they met the following criteria: patients who are diagnosed with IGM as confirmed by histopathology of the surgical excision specimen, patients who underwent surgical excision, patients who received postoperative oral Yanghe decoction, and patients who were followed up at The Affiliated People’s Hospital of Ningbo University. The exclusion criteria were as follows: patients who were followed up for less than 3 months or were lost to follow-up and patients who received steroids orally after surgery. Patients who were treated with surgical management only and surgical management combined with oral Yanghe decoction were included in Groups A and B, respectively. The study was approved by the hospital ethics committee (NO. 2020-002, 107-W-066, January 31, 2020).

2.2. Surgical management

Wide surgical excision of the lesions was performed for patients diagnosed with IGM. In some patients with disfiguring, 1-stage mammoplasty techniques were used to ensure postoperative cosmetic effects.

2.3. Yanghe decoction regimen

Patients were consulted by a TCM physician after the diagnosis of IGM was confirmed by pathological examination of the resected sections. Yanghe decoction was prescribed and administered daily. Patients were administered the Yanghe decoction 30 minutes after meals in the morning and evening for 3 months. TCM herbs used in the Yanghe decoction were manufactured at a standardized facility (Ningbo Yinzhou Mingbei Pharmaceutical Co Ltd, China). The ingredients in the Yanghe decoction included Radix Rehmanniae Preparata 13 g, Ephedra 2 g, Colla Cornus Cervi 20 g, Brassica alba Boiss 6 g, Cinnamomum Cassia 3 g, Raw Licorice 3 g, and Rhizoma Zingiberis Preparata 3 g (Fig. 1).

2.4. Assessment and Follow-up

Patients were assessed every month during the first 6 months and then every 3 months for the next 6 months. Six-month follow-up was initiated at the beginning of the second year. Standard evaluations included physical examination, ultrasound, mammary radiography, magnetic resonance imaging, and core needle biopsy. Patients received all or some of these modalities based on their condition.

2.5. Criteria for complete remission (CR)

Complete remission (CR) was defined as the disappearance of local swelling, erythema, tenderness, and absence of any anomalies upon ultrasound examination after treatment.

2.6. Data collection

Patient demographics and characteristics, hospital stay, CR time, cases of CR, recurrent cases, and follow-up time were recorded.

2.7. Statistical analysis

SPSS 17.0 (SPSS, Inc., Chicago, IL) was used for statistical analysis. Continuous variables were recorded as mean values ± standard deviations and were compared using independent-samples t tests. Chi-square tests were used to analyze categorical variables. The differences between the two groups were assessed using the Mann–Whitney U test. P-value <.05 was considered statistically significant.

3. Results

3.1. Demographics and characteristics of the study cases

There were no statistically significant differences in marital status (P =.546), lactational history (P = .367), or preoperative treatment (P = .706) between the groups (Table 1). There were no significant differences with respect to lesion location (P = .439), lesion size (P = .761), duration of illness (P = .752), surgical methods (P = .552), or comorbidities (P = .736) between groups (Table 1).

3.2. Outcomes of the two treatments

The hospital stay and follow-up times were similar between the groups (P = .625 and P = .896, respectively). Group B had shorter CR time (76.1 ± 15.2 vs 84.0 ± 12.2 days, P = .043), higher CR rate (96.4% vs 76.0%, P = .28), and lower recurrence rate (0% vs 16.0%, P = .28) (Table 2). No patient showed intolerance to the oral Yanghe decoction in Group B. No Yanghe decoction-related side effects were observed in Group B.

4. Discussion

IGM is a rare benign inflammatory disease of the breast, characterized by a recurrent disease course; morbidity due to IGM can be debilitating. It needs to be differentiated from other tumor or tumor-like mesenchymal lesions of the breast, such as plasma cell mastitis and sarcoma. Generally, the diagnosis can be confirmed by histopathology of core needle biopsy or excision of the lesion. The optimal treatment of patients with IGM remains uncertain, and various treatments are described in the literature. Some studies have shown that corticosteroid administration is effective, alone or in combination with surgical intervention. Nevertheless, corticosteroids has a high failure rate and possible side effects associated with long-term use, including weight gain, osteoporosis, hyperglycemia, Cushings syndrome, and even life-threatening pulmonary thrombosis. Some researchers reported that close observation was the best management for IGM. However, observation alone can lead to a prolonged disease process and increased risk of disease exacerbation leading to ultimate skin rupture. The increased psychological pressure on patients is an issue that needs to be avoided when choosing this “wait and watch” approach. Surgical excision plays an important role in the treatment of IGM, achieving rapid remission. Some have argued that excision can result in undesirable disfigurement. In our study, mammoplasty was performed to minimize this cosmetic problem. Because of the recurrent nature of IGM, the recurrence rate of the surgical intervention varied from 6.7% to 22.2%. In particular, patients with inflammatory changes have a higher risk of recurrence and recurrences are frequent after surgical excision. Although IGM is a benign disease, recurrence after...
surgery adds extra economic and psychological burdens on patients. Therefore, reducing postoperative recurrence is an important issue for breast surgeons. Shin et al\(^{23}\) focused on oral steroids after surgery to reduce recurrence; however, the outcome was unsatisfactory. Furthermore, the optimal dose and period of treatment are unknown, and there are side effects caused by steroids.

TCM is commonly used as a complement to evidence-based therapies for illnesses; it has the unique advantages of efficacy, convenience, safety, and low cost.\(^{24}\) TCM has been considered as a more “natural” method to boost human immunity and to achieve high quality of life. Patients have selected TCM, and its demand has been increasing over the past several decades, including in Western countries. Yanghe decoction was first
described by Wang Hongxu during the Qing Dynasty. It consists of 6 herbs and deer-horn gelatin. According to TCM theory, Yanghe decoction warms Yang, nourishes blood, disperses cold, and activates stagnancy, and is also used for treating breast cancer.\(^{[25]}\) Due to the safe nature of TCM, contradictions for surgical excision of IGM require further study. Prospective randomized control studies are needed to investigate the value of TCM in the treatment of IGM.

In conclusion, in IGM patients, the postoperative Yanghe decoction regimen can achieve more rapid recovery after surgery. Surgical management combined with postoperative oral Yanghe decoction yields a higher CR rate and lower recurrence rate than surgery alone. It is worthwhile to investigate the effect of TCM in IGM in future studies.

**Acknowledgments**

We acknowledge the work of the nurses and doctors of The Affiliated People’s Hospital of Ningbo University involved in the surgeries and treatments of IGM.

**Author contributions**

Conceptualization: Xing Zhang.

Data curation: Xing Zhang, Jing Li.

Formal analysis: Xing Zhang.

Investigation: Xing Zhang, Jing Li, Xian-jie Hu.

Methodology: Xing Zhang, Xian-jie Hu.

Project administration: Xian-jie Hu.

Resources: Xian-jie Hu.

Software: Xing Zhang.

Supervision: Xing Zhang.

Writing – original draft: Xing Zhang.

Writing – review & editing: Xing Zhang.

**References**

[1] Kessler E, Wolff Y. Granulomatous mastitis: a lesion clinically simulating carcinoma. Am J Clin Pathol 1972;58:642–6.

[2] Kaviani A, Vasigh M, Omranpour R, et al. Idiopathic granulomatous mastitis: looking for the most effective therapy with the least side effects according to the severity of the disease in 374 patients in Iran. Breast J 2019;25:672–7.

[3] Wolfrum A, Kümmel S, Theuerkauf I, et al. Granulomatous mastitis: a therapeutic and diagnostic challenge. Breast Care (Basel) 2018;13:413–8.

[4] Çetin K, Sikar HE, Göret NE, et al. Comparison of topical, systemic, and combined therapy with steroids on idiopathic granulomatous mastitis: a prospective randomized study. World J Surg 2019;43:2863–73.

[5] Alrayes A, Almarzooq R, Abdulla HA. Surgical treatment of granulomatous mastitis: our experience in Bahrain. Breast J 2019;25:938–62.

[6] Postolova A, Troxell ML, Wapnir IL, et al. Methotrexate in the treatment of idiopathic granulomatous mastitis. J Rheumatol 2019;15:924–7.

[7] Davis J, Cocco D, Matz S, et al. Re-evaluating if observation continues to be the best management of idiopathic granulomatous mastitis. Surgery 2019;166:1176–80.

[8] Yilmaz TU, Gürbel B, Guler SA, et al. Scoring idiopathic granulomatous mastitis: an effective system for predicting recurrence? Eur J Breast Health 2018;14:112–6.

[9] Barreto DS, Sedwick EL, Nagi CS, et al. Granulomatous mastitis: etiology, imaging, pathology, treatment, and clinical findings. Breast Cancer Res Treat 2018;171:527–34.

[10] Palmieri A, D’Orazio V, Martino G, et al. Plasma cell mastitis in men: a single-center experience and review of the literature. In Vivo 2016;30:727–32.

---

**Table 1**

The demographical and clinical characteristics in patients with IGM between 2 groups.

| Variable                        | Group A (n = 25) | Group B (n = 28) | P  |
|---------------------------------|-----------------|-----------------|----|
| Age, yrs                        | 35.2 ± 7.2      | 34.1 ± 4.6      | .510 |
| Gender, n (%)                   |                 |                 | .546 |
| Female                          | 25 (100%)       | 28 (100%)       | .546 |
| Marital status                  |                 |                 | .367 |
| Married                         | 22 (88.0%)      | 26 (92.9%)      | .287 |
| Unmarried                       | 3 (12.0%)       | 2 (7.1%)        | .287 |
| Lactational history, n (%)      |                 |                 | .367 |
| Yes                             | 19 (76.0%)      | 24 (85.7%)      | .298 |
| No                              | 6 (24.0%)       | 4 (14.3%)       | .298 |
| Preoperative treatment          |                 |                 | .706 |
| Yes                             | 6 (24.0%)       | 8 (28.6%)       | .706 |
| No                              | 19 (76.0%)      | 20 (71.4%)      | .706 |
| Lesion location                 |                 |                 | .439 |
| Central area                    | 1 (4.0%)        | 2 (7.1%)        | .439 |
| Upper outer quadrant            | 13 (52.0%)      | 16 (57.1%)      | .761 |
| Lower outer quadrant            | 6 (24.0%)       | 7 (25.0%)       | .761 |
| Upper inner quadrant            | 2 (8.0%)        | 3 (10.7%)       | .761 |
| Lower inner quadrant            | 3 (12.0%)       | 0               | .761 |
| Lesion size (T)                 |                 |                 | .761 |
| ≤ 2 cm                          | 19 (76.0%)      | 23 (82.1%)      | .761 |
| 2 cm < T ≤ 5 cm                 | 4 (16.0%)       | 4 (14.3%)       | .761 |
| > 5 cm                          | 2 (8.0%)        | 1 (3.6%)        | .761 |
| Duration of illness             | 3.0 ± 0.7       | 3.0 ± 0.4       | .761 |
| Surgical methods                |                 |                 | .552 |
| Wide surgical excision          | 22 (88.0%)      | 23 (82.1%)      | .552 |
| Wide surgical excision and mammoplasty | 3 (12.0%)       | 5 (17.9%)       | .552 |
| Comorbidities, n (%)            |                 |                 | .736 |
| Diabetes mellitus               | 1 (4.0%)        | 2 (7.1%)        | .736 |
| Hypertension                    | 1 (4.0%)        | 1 (3.6%)        | .736 |

**Table 2**

Outcome of IGM between 2 groups.

| Variable                      | Group A (n = 25) | Group B (n = 28) | P  |
|-------------------------------|-----------------|-----------------|----|
| Hospital stay, d              | 2.2 ± 1.2       | 2.4 ± 1.1       | .625 |
| Complete remission time, d    | 84.0 ± 12.2     | 76.1 ± 15.2     | .043 |
| Cases of complete remission, n (%) | 19 (76.0%)       | 27 (96.4%)      | .028 |
| Recurrent cases, n (%)        | 4 (16.0%)       | 0 (0%)          | .028 |
| Follow-up time, mo            | 12.2 ± 10.0     | 12.0 ± 10.2     | .896 |
[11] Pasta V, Monti M, Cialini M, et al. Primitive sarcoma of the breast: new insight on the proper surgical management. J Exp Clin Cancer Res 2015;34:72.
[12] Lei X, Chen K, Zhu L, et al. Treatments for idiopathic granulomatous mastitis: systematic review and meta-analysis. Breastfeed Med 2017;12:415–21.
[13] Yukawa M, Watatani M, Isono S, et al. Management of granulomatous mastitis: a series of 13 patients who were evaluated for treatment without corticosteroids. Int Surg 2015;100:774–82.
[14] Bouton ME, Jayaram L, O’Neill PJ, et al. Management of idiopathic granulomatous mastitis with observation. Am J Surg 2015;210:258–62.
[15] Ahmed YS, Abd El Maksoud W. Evaluation of therapeutic mammoplasty techniques in the surgical management of female patients with idiopathic granulomatous mastitis with mild to moderate inflammatory symptoms in terms of recurrence and patients’ satisfaction. Breast Dis 2016;36:37–45.
[16] Elzahaby IA, Khater A, Fathi A, et al. Etologic revelation and outcome of the surgical management of idiopathic granulomatous mastitis; an Egyptian centre experience. Breast Dis 2016;36:115–22.
[17] Morris D, Damaskos G, Davakis S, et al. Is idiopathic granulomatous mastitis a surgical disease? The jury is still out. Ann Transl Med 2017;5:309.
[18] Akcan A, Oz AB, Dogan S, et al. Idiopathic granulomatous mastitis: comparison of wide local excision with or without corticosteroid therapy. Breast Care (Basel) 2014;9:111–5.
[19] Kiyak G, Dumlul EG, Kilinc I, et al. Management of idiopathic granulomatous mastitis: dilemmas in diagnosis and treatment. BMC Surg 2014;14:66.
[20] Hur SM, Cho DH, Lee SK, et al. Experience of treatment of patients with granulomatous lobular mastitis. J Korean Surg Soc 2013;85:1–6.
[21] Neel A, Hello M, Cottereau A, et al. Long-term outcome in idiopathic granulomatous mastitis: a western multicentre study. QJM 2013;106:433–41.
[22] Tan QT, Tay SP, Gudi MA, et al. Granulomatous mastitis and factors associated with recurrence: an 11-year single-centre study of 113 patients in Singapore. World J Surg 2019;43:1737–45.
[23] Shin YD, Park SS, Song YJ, et al. Is surgical excision necessary for the treatment of Granulomatous lobular mastitis? BMC Womens Health 2017;17:49.
[24] Lü JM, Yao Q, Chen C. Ginseng compounds: an update on their molecular mechanisms and medical applications. Curr Vasc Pharmacol 2009;7:293–302.
[25] Zeng L, Yang K. Exploring the pharmacological mechanism of Yanghe Decoction on HER2-positive breast cancer by a network pharmacology approach. J Ethnopharmacol 2017;199:68–85.
[26] Xu X, Wan Y, Gong L, et al. Chinese herbal medicine Yanghe decoction for knee osteoarthritis: a protocol for systematic review and meta-analysis. Medicine (Madr) 2020;99:e21877.
[27] Wang Y, Xiao X. Clinical efficacy of modified Yanghe decoction in ankylosing spondylitis: a randomized controlled trial. Med Sci Monit 2018;24:2912–8.